Cervical cancer develops when cells in the cervix are transformed by a persistent infection with certain strains of human papillomavirus, known as HPV. The virus is necessary for the vast majority of cases, but infection alone is not enough. A chain of events involving the immune system, other risk factors, and sometimes years of slow cellular change determines whether an HPV infection becomes cancer. That process, and the many points at which it can be interrupted, is worth understanding in detail.
HPV Is the Starting Point for Nearly Every Case
HPV is one of the most common sexually transmitted infections in the world, yet only a fraction of the more than 100 known genotypes pose a serious cancer risk. At least 15 of these are classified as high-risk, or oncogenic, types. Two of them, HPV 16 and HPV 18, account for roughly 70 percent of all cervical cancers worldwide.1PubMed. Natural history and epidemiology of HPV infection and cervical cancer Other high-risk types, including HPV 31, 33, 45, 52, and 58, make up most of the remainder.
The relationship between high-risk HPV and cervical cancer is described in the research literature as “necessary but not sufficient.” That means the virus is essential to the transformation of cervical cells, but having the virus does not guarantee cancer will develop. A variety of cofactors and molecular events influence whether it does.2PubMed Central. Human papillomavirus and cervical cancer This distinction matters because it explains why HPV is extraordinarily common while cervical cancer, though serious, is comparatively rare.
How HPV Reaches the Cervix
HPV spreads primarily through skin-to-skin or skin-to-mucosa contact. Sexual transmission is by far the most documented route, including vaginal, anal, and oral sex. Condoms reduce the risk but do not eliminate it, because the virus can infect skin in the genital area that a condom does not cover.3PubMed Central. Non-sexual HPV transmission and role of vaccination for a better future There is also research suggesting non-sexual routes of transmission, including vertical transmission from mother to newborn and, in rare cases, contact with contaminated surfaces. These non-sexual pathways are far less common and are not the main driver of cervical cancer.
Most sexually active people will be exposed to HPV at some point in their lives. The virus targets the basal cells of the cervical epithelium, the deepest layer of cells lining the cervix. It typically gains access through tiny breaks or abrasions in the tissue. Once inside those cells, the virus can begin producing proteins that hijack normal cell growth.
Why Most Infections Never Become Cancer
About 80 to 90 percent of HPV infections are transient, meaning the immune system clears them on its own within about two years.4PubMed Central. Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite During these infections, you might never know you were infected. The virus may cause no symptoms at all, or it might trigger minor changes in cervical cells that resolve without treatment.
The trouble begins when the immune system fails to clear a high-risk HPV infection and the virus persists. Persistent infection is the single most important step toward cervical cancer. Over months and years, two viral proteins called E6 and E7 interfere with the cell’s natural defenses. These proteins disable p53 and pRb, two of the body’s most important tumor-suppressor proteins, which normally act as brakes on uncontrolled cell growth.5PubMed. Silencing E6/E7 Oncoproteins in SiHa Cells Treated with siRNAs and Oroxylum indicum Extracts Induced Apoptosis by Upregulating p53/pRb Pathways With those brakes disabled, infected cells can accumulate genetic damage and begin multiplying abnormally.
The Slow Progression from Abnormal Cells to Cancer
Cervical cancer does not appear overnight. Between the initial persistent infection and a full-blown cancer, there is usually a long window of precancerous changes called cervical intraepithelial neoplasia, or CIN. These are graded from mild (CIN 1) to severe (CIN 3). Low-risk HPV types tend to cause CIN 1 and genital warts, while high-risk types, especially HPV 16 and 18, are found in the majority of CIN 2 and CIN 3 lesions and in about 90 percent of cervical cancers.6PubMed Central. Aetiology, pathogenesis, and pathology of cervical neoplasia
Not every precancerous lesion advances. Research on the natural history of these lesions suggests that about 10 percent of CIN 1 cases progress to CIN 3, while around 20 percent of CIN 2 cases do. Among CIN 3 cases, at least 12 percent go on to become invasive cancer.7PubMed Central. Aetiology, pathogenesis, and pathology of cervical neoplasia Many CIN 1 and even some CIN 2 lesions regress on their own. This gradual timeline, often spanning 10 to 20 years from infection to cancer, is the reason screening is so effective at catching the disease early.
Cofactors That Raise the Risk
If HPV is necessary but not sufficient, what else tips the balance? Several cofactors have been studied extensively. None of them cause cervical cancer on their own, but in a person already carrying a persistent high-risk HPV infection, they can increase the chance of progression.
Smoking
Tobacco smoke has a surprisingly direct relationship with the cervix. Cigarette byproducts, including benzo[a]pyrene, nicotine, and certain nitrosamines, have been measured in cervical mucus. Benzo[a]pyrene may increase the amplification of the HPV genome, raising the likelihood that viral DNA integrates into the host cell’s DNA, a milestone event in cervical cancer development. Long-term nicotine exposure also promotes cell proliferation and suppresses the local immune response, making it harder for the body to fight off an existing infection.8PubMed Central. Smoking and Cervical Cancer
Long-Term Oral Contraceptive Use
Multiple large studies have found that using combined oral contraceptives for five years or longer is associated with roughly double the risk of cervical cancer compared to never using them. A collaborative reanalysis of data from over 16,000 women with cervical cancer and 35,000 without found that current users with five or more years of use had a relative risk of about 1.9 compared to never-users. The reassuring finding is that the increased risk fades after stopping, and by ten or more years after cessation it returns to baseline.9PubMed. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies The exact mechanism is still debated, but hormonal effects on cervical tissue and the immune microenvironment are suspected.
Having Many Pregnancies
Among women already positive for HPV, having a high number of full-term pregnancies increases the risk of squamous-cell cervical cancer. A large international study found that women with seven or more full-term pregnancies had roughly four times the risk compared to women who had never given birth, and about twice the risk compared to women with one or two pregnancies.10The Lancet. Role of parity and human papillomavirus in cervical cancer: The IARC multicentric case-control study Hormonal changes during pregnancy, mechanical trauma to the cervix during delivery, and immune shifts during gestation may all contribute.
Immunosuppression, Especially HIV
A weakened immune system is one of the strongest cofactors. HIV-positive women face a substantially higher risk of cervical cancer, and the risk climbs as immune function declines. A multi-cohort study found that compared to HIV-negative women, those with HIV and a CD4 count below 200 had roughly eight times the incidence of invasive cervical cancer. Even HIV-positive women with relatively preserved immune function (CD4 above 350) had more than double the rate.11PubMed Central. Invasive cervical cancer risk among HIV-infected women: A North American multi-cohort collaboration prospective study HIV-driven immunosuppression increases HPV persistence, and certain HIV proteins may actively promote the oncogenic processes that E6 and E7 set in motion.12PubMed Central. Molecular, immunological and oncogenic mechanisms of cervical cancer mediated by HPV/HIV co-infection, clinical implication and management Other forms of immunosuppression, such as medications taken after organ transplantation, carry similar concerns.
Chlamydia Co-Infection
Chlamydia trachomatis, another common sexually transmitted infection, has emerged as a notable cofactor. A meta-analysis found that women co-infected with both HPV and chlamydia had about four times the risk of cervical cancer compared to those without chlamydia.13PubMed Central. Chlamydia Trachomatis Infection-Associated Risk of Cervical Cancer: A Meta-Analysis One proposed explanation is that chlamydia reduces the number of immune cells available to present HPV antigens, allowing HPV to evade the cell-mediated immune response and persist longer. Chlamydia may also damage the cervical lining, giving HPV easier access to the basal cells it needs to infect.14PubMed Central. Chlamydia Infection as a Risk Factor for Cervical Cancer: A Systematic Review and Meta-Analysis
The Role of the Vaginal Microbiome
An emerging area of research is the influence of the vaginal microbiome on HPV persistence. A healthy vaginal microbiome is typically dominated by Lactobacillus species, which maintain an acidic environment that helps keep pathogens in check. When this community shifts to a more diverse, less Lactobacillus-dominated state, known as dysbiosis, HPV appears more likely to persist. One study found significantly different microbial compositions between women whose HPV infections cleared and those whose infections persisted, with persistent infections showing higher levels of bacteria like Prevotella, Sphingomonas, and Anaerococcus.15PubMed. Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection
More recent work has refined this picture. The transition from communities dominated by Lactobacillus crispatus to dysbiotic states enriched in bacteria like Gardnerella and Sneathia is now considered a strong predictor of persistent high-risk HPV infection and progression to high-grade precancerous lesions.16PubMed Central. The vaginal microbiome in HPV persistence and cervical cancer progression This raises the possibility that the vaginal microbiome could eventually serve as a non-invasive biomarker to help identify women at higher risk, though routine clinical use is not there yet.
Not All HPV 16 Is the Same
Even within a single HPV type, genetic variation matters. HPV 16, the type responsible for the largest share of cervical cancers, can be divided into multiple sub-lineages, and these carry different levels of risk depending on the geographic population. A large international study analyzing whole viral genomes from over 7,000 HPV 16-positive women found that certain sub-lineages raised cancer risk substantially compared to the most common reference lineage. For example, the A4 sub-lineage carried more than six times the risk in East Asian populations and nearly four times the risk in North America. The D lineage similarly showed a strongly elevated risk in the Americas.17Papillomavirus Research. Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women
Interestingly, some variants that increase risk in one region may be neutral or even protective in another. A separate worldwide study found that a specific European variant (EUR-350G) was overrepresented among cervical cancer cases in South and Central America but significantly underrepresented in cases from East Asia and Europe.18British Journal of Cancer. HPV16 genetic variation and the development of cervical cancer worldwide These patterns suggest that the interaction between viral genetics and host genetics, including immune system genes, shapes risk in complex ways. Variations in a person’s HLA genes, which govern how the immune system recognizes infected cells, also influence whether an HPV infection persists and progresses.19PubMed. HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer
Can You Get Cervical Cancer Without HPV?
Yes, but it is uncommon. Overall, roughly 3 to 8 percent of cervical cancer cases test negative for HPV.20Journal of Clinical Oncology. Molecular characteristics of non-human papillomavirus driven cervical adenocarcinoma and adenosquamous carcinoma These cases cluster disproportionately among adenocarcinomas, a subtype that arises from the glandular cells of the cervix rather than the squamous cells. About 15 to 20 percent of cervical adenocarcinomas are HPV-negative, compared to a very small fraction of squamous-cell cancers.21PubMed Central. HPV-Negative Adenocarcinomas of the Uterine Cervix: From Molecular Characterization to Clinical Implications
HPV-negative cervical cancers tend to have different molecular profiles and, in some studies, a worse prognosis. Their drivers are not fully understood but may include other genetic mutations rather than viral oncoproteins. A historically notable non-HPV cause is diethylstilbestrol (DES), a synthetic estrogen prescribed to pregnant women from the 1940s through the early 1970s to prevent miscarriage. Daughters exposed to DES in utero had a small but real risk of developing a rare clear-cell adenocarcinoma of the vagina and cervix, typically diagnosed between the ages of 14 and 23. The estimated cumulative risk through age 34 was about 1 in 1,000 exposed women.22PubMed. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update DES has not been prescribed to pregnant women for decades, so this particular pathway has largely become a historical footnote, but it remains a useful reminder that non-viral exposures can occasionally drive cervical malignancies.
Screening Catches the Disease Before It Starts
Because cervical cancer takes years to develop from precancerous lesions, screening has the potential to catch it at a stage where simple treatment can prevent cancer entirely. Two main approaches are used: the Pap test (which looks for abnormal cells under a microscope) and HPV DNA testing (which checks for the presence of high-risk HPV strains).
HPV testing is substantially more sensitive. A randomized trial comparing the two head-to-head found that HPV testing detected precancerous lesions (CIN 2 or 3) with a sensitivity of about 95 percent, while the Pap test caught only about 55 percent.23PubMed. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer Other studies have found similar gaps, with HPV testing consistently around 40 to 60 percent more sensitive than cytology alone for detecting high-grade lesions.24British Journal of Cancer. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications The trade-off is that HPV testing has somewhat lower specificity, meaning it flags more women who have a harmless, transient infection and do not actually need treatment. This is why many screening guidelines now recommend HPV testing as the primary method, often with a Pap test used as a follow-up when the HPV test is positive, rather than the other way around.
Vaccination and What It Does
HPV vaccines work by training the immune system to recognize and block HPV before it can establish an infection. They use virus-like particles made from the outer shell of HPV, which trigger a strong antibody response without containing any viral DNA that could cause infection. The antibodies generated by vaccination persist at levels many times higher than those produced by a natural infection, maintained for at least four years in early studies and now shown to last much longer in ongoing follow-up.25PubMed. Prophylactic HPV vaccines: underlying mechanisms
Current vaccines protect against HPV 16 and 18 and, in the case of the nine-valent vaccine, against several additional high-risk and low-risk types. Vaccination is most effective before any exposure to HPV, which is why it is recommended for preteens, but it provides benefit to older individuals who have not yet been exposed to all of the covered types. In countries with high vaccination rates, population-level reductions in precancerous cervical lesions have already been documented. Vaccination does not treat an existing HPV infection, and it does not replace screening, so both strategies work together. A vaccinated person still benefits from regular screening because the vaccines do not cover every high-risk HPV type.
The Vaginal Microbiome as an Emerging Screening Tool
The research linking vaginal microbiome composition to HPV persistence has opened a question that cervical cancer screening may eventually need to reckon with. If certain microbial profiles reliably predict which women are most likely to see a high-risk HPV infection progress rather than clear, a microbiome test could theoretically be layered on top of existing HPV screening to improve risk stratification. Women with both a positive HPV test and a dysbiotic vaginal community might warrant closer surveillance, while those with a Lactobacillus-dominated profile might safely extend their screening interval. This remains a research question rather than a clinical reality, but clinical trials are underway, and the idea has gained enough traction that it appears regularly in the gynecologic oncology literature.26PubMed Central. The vaginal microbiome in HPV persistence and cervical cancer progression The appeal is practical: a vaginal swab is already collected during HPV testing, and analyzing the microbial composition of that same swab adds information without adding a separate procedure.